Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer.
Ovarian cancer is the most lethal of all gynecological malignancies, due in part to the diagnosis at an advanced stage caused by the lack of specific signs and symptoms and the absence of reliable tests for screening and early detection. Most patients will respond initially to treatment but about 70% of them will suffer a recurrence. Therefore, new therapeutic modalities are urgently needed to overcome chemoresistance observed in ovarian cancer patients. Evidence accumulates suggesting that the insulin/insulin growth factor (IGF) pathways could act as a good therapeutic target in several cancers, including ovarian cancer. In this paper, we will focus on the role of insulin/IGF in ovarian cancer tumorigenesis and treatment.
Beauchamp
Marie-Claude
MC
Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, QC, Canada H3T 1E2.
Yasmeen
Amber
A
Knafo
Ariane
A
Gotlieb
Walter H
WH